|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1996-10-30
|
|
pubmed:abstractText |
Topotecan is a specific inhibitor of topoisomerase I. Preclinical data have indicated that topoisomerase I inhibitors demonstrate more efficacy and have a greater therapeutic index with prolonged continuous exposure. The feasibility of this concept in humans using a 21-day continuous infusion of topotecan has been reported. We conducted a phase II study of this 21-day continuous topotecan administration schedule in patients with locally advanced, unresectable or metastatic colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:CreemersG JGJ,
pubmed-author:GerritsC JCJ,
pubmed-author:HarteveldMM,
pubmed-author:HudsonII,
pubmed-author:LoosWW,
pubmed-author:PlantingA SAS,
pubmed-author:SchellensJ HJH,
pubmed-author:StoterGG,
pubmed-author:VerweijJJ,
pubmed-author:de Boer-DennertMM,
pubmed-author:van BeurdenV MVM,
pubmed-author:van der BurgM EME
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2540-5
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8823333-Adult,
pubmed-meshheading:8823333-Aged,
pubmed-meshheading:8823333-Antineoplastic Agents,
pubmed-meshheading:8823333-Camptothecin,
pubmed-meshheading:8823333-Colorectal Neoplasms,
pubmed-meshheading:8823333-Female,
pubmed-meshheading:8823333-Humans,
pubmed-meshheading:8823333-Infusion Pumps,
pubmed-meshheading:8823333-Male,
pubmed-meshheading:8823333-Middle Aged,
pubmed-meshheading:8823333-Topotecan
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdom Cancer Institute, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
